Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2019.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 28, 2020, at 1 p.m. (ET).
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2019 results after the financial markets close on Monday, February 24, 2020.
Brighter AB (publ) has today completed the previously announced acquisition of Nectarine Health, a Swedish innovation company developing AI-care solutions within the elderly care sector.
#product & service
The interview with the CEO of DreaMed is a part of a partnership between Beyond Type 1 and DreaMed Diabetes.
The RocheDiabetes Care Platform is one of the key components of Roche’s open ecosystem that connects healthcare professionals seamlessly with people with diabetes. The modular based platform brings together diabetes-relevant data from various sources within a single digital solution, thus providing meaningful, actionable insights for a more personalised approach to diabetes care.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for the first fiscal quarter ended December 31, 2019. This represents an increase of 1.6 percent as reported over the prior-year period, or 2.5 percent on a currency-neutral basis.
Cecelia Health is proud to support the 2020 Novo Nordisk Donnelly Award Scholarship for the second year in a row. The 2020 Novo Nordisk Donnelly Awards will award $80,000 in scholarships to male and female athletes aged 14-21 and in good academic standing, who have diabetes and play tennis competitively in tournaments or on their school team.
mySugr, a digital health company committed to simplifying life for people with diabetes, announced its coaching program has been accredited by the American Association of Diabetes Educators (AADE). This prestigious accreditation status distinguishes mySugr as a leader in reinventing diabetes care and improving health outcomes for the millions of people living with the condition.
#coaching
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and financial results for the third quarter ended December 31, 2019.